Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Cash: 2017-2024

Historic Change in Cash for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $288.5 million.

  • BridgeBio Pharma's Change in Cash rose 25.16% to -$106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.2 million, marking a year-over-year increase of 304.04%. This contributed to the annual value of $288.5 million for FY2024, which is 1402.42% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Change in Cash is $288.5 million, which was up 1,402.42% from -$22.2 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Change in Cash ranged from a high of $288.5 million in FY2024 and a low of -$22.2 million during FY2023.
  • For the 3-year period, BridgeBio Pharma's Change in Cash averaged around $95.6 million, with its median value being $20.5 million (2022).
  • In the last 5 years, BridgeBio Pharma's Change in Cash tumbled by 207.96% in 2023 and then spiked by 1,402.42% in 2024.
  • BridgeBio Pharma's Change in Cash (Yearly) stood at -$5.5 million in 2020, then surged by 782.96% to $37.7 million in 2021, then tumbled by 45.55% to $20.5 million in 2022, then slumped by 207.96% to -$22.2 million in 2023, then spiked by 1,402.42% to $288.5 million in 2024.